2426-19-9 Usage
Description
5-METHOXY-ALPHA-OXO-1H-INDOLE-3-ACETYL CHLORIDE is an organic chemical compound that serves as an intermediate in the synthesis of various tryptamine-based substances. It is characterized by its unique molecular structure, which includes a 5-methoxy indole core and an acetyl chloride functional group. 5-METHOXY-ALPHA-OXO-1H-INDOLE-3-ACETYL CHLORIDE is primarily used in the development of psychedelic tryptamines and has potential applications in the fields of forensic science and research.
Uses
Used in Pharmaceutical Research:
5-METHOXY-ALPHA-OXO-1H-INDOLE-3-ACETYL CHLORIDE is used as a synthetic intermediate for the production of 5-Methoxy-N-methyl-N-isopropyl Tryptamine (M271680), a psychedelic tryptamine. 5-METHOXY-ALPHA-OXO-1H-INDOLE-3-ACETYL CHLORIDE is of interest to researchers due to its potent inhibition of serotonin and norepinephrine re-uptake, which may provide insights into the development of novel treatments for various psychiatric and neurological disorders.
Used in Forensic Applications:
In the field of forensic science, 5-METHOXY-ALPHA-OXO-1H-INDOLE-3-ACETYL CHLORIDE is utilized for the analysis and identification of synthetic tryptamines, particularly M271680. 5-METHOXY-ALPHA-OXO-1H-INDOLE-3-ACETYL CHLORIDE can be used as a reference material to help forensic chemists detect and characterize these substances in criminal investigations.
Used in Neurochemical Research:
5-METHOXY-ALPHA-OXO-1H-INDOLE-3-ACETYL CHLORIDE is used as a research tool to study the effects of M271680 on monoamine neurotransmitter systems. Its ability to inhibit the re-uptake of serotonin and norepinephrine without affecting dopamine re-uptake makes it a valuable compound for understanding the complex interactions between these neurotransmitters and their role in various physiological and pathological processes.
Used in Drug Development:
Although not directly used as a drug itself, 5-METHOXY-ALPHA-OXO-1H-INDOLE-3-ACETYL CHLORIDE plays a crucial role in the development of new pharmaceuticals targeting the monoamine system. By understanding the structure-activity relationships of compounds like M271680, researchers can design more effective and selective drugs for the treatment of conditions such as depression, anxiety, and other mood disorders.
Check Digit Verification of cas no
The CAS Registry Mumber 2426-19-9 includes 7 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 4 digits, 2,4,2 and 6 respectively; the second part has 2 digits, 1 and 9 respectively.
Calculate Digit Verification of CAS Registry Number 2426-19:
(6*2)+(5*4)+(4*2)+(3*6)+(2*1)+(1*9)=69
69 % 10 = 9
So 2426-19-9 is a valid CAS Registry Number.
InChI:InChI=1/C11H8ClNO3/c1-16-6-2-3-9-7(4-6)8(5-13-9)10(14)11(12)15/h2-5,13H,1H3
2426-19-9Relevant articles and documents
A one-pot tandem Pictet-Spengler-Diels-Alder synthesis of apoyohimbines from 3-carbomethoxy-2-(formylmethyl)-3-sulfolene
Leonard, John,Hague, Andrew B.,Jones, Martin F.
, p. 3071 - 3074 (1997)
Pictet-Spengler reactions were carried out between 3-carbomethoxy-2-(formylmethyl)-3-sulfolene and tryptamines. Without isolation, die products were converted with complete stereoselectivity into apoyohimbine derivatives, via sulfur dioxide extrusion followed by intramolecular Diels-Alder cyclisation.
PHARMACEUTICAL COMPOSITION COMPRISING 5-METHOXY-N, N-DIMETHYLTRYPTAMINE
-
Page/Page column 6, (2021/12/31)
An intranasal composition comprises a dosage amount of 50 to 150 mg / ml of 5-methoxy-N, N-dimethyltryptamine (5 MeODMT) in a liquid medium, 5MeODMT being formulated as a chloride salt of 5MeODMT (chlrorhydrate of 5MeODMT) and hydrochloride of 5MeODMT bei
2-(1H-INDOLE-3-CARBONYL)-THIAZOLE-4-CARBOXAMIDE DERIVATIVES AND RELATED COMPOUNDS AS ARYL HYDROCARBON RECEPTOR (AHR) AGONISTS FOR THE TREATMENT OF E.G. ANGIOGENESIS IMPLICATED OR INFLAMMATORY DISORDERS
-
Paragraph 00162; 00217, (2021/06/26)
2-(1H-lndole-3-carbonyl)-thiazole-4-carboxamide derivatives and the corresponding imidazole, oxazole and thiophene derivatives and related compounds as aryl hydrocarbon receptor (AHR) agonists for the treatment of angiogenesis implicated disorders, such as e.g. retinopathy, psoriasis, rheumatoid arthritis, obesity and cancer, or inflammatory disorders. The present description discloses the synthesis and characterisation of exemplary compounds as well as pharmacological data thereof (e.g. pages 27 to 32 and 59 to 219; examples 1 to 8; compounds 1-1 to 1-97; tables 1-a, 2 and 3).